NanoViricides President Dr. Diwan Gave Invited Talks on Regulatory Aspects of Nanomedicines
SHELTON, CONNECTICUT -- Monday, November, 7, 2016 -- NanoViricides, Inc. (NYSE MKT: NNVC) (the "Company") reports that its President Dr. Anil Diwan was recently invited to participate in certain pharmaceutical industry meetings to comment on regulatory aspects of nanomedicines.
On September 21, 2016, Dr. Anil Diwan, President and Chairman of the Company, was invited as panel participant to discuss "Regulatory Landscape: What's Needed to Drive Innovation" in the "Anti-Infectives-Rx 2016" Conference organized by Boston Biotech Conferences and held at the Harvard Medical School - Joseph B. Martin Conference Center, Boston, MA.
On September, 19, 2016, Dr. Diwan was invited to present two talks at the "Public Health and Emerging Microbial Threats, 14th Annual International Conference" (PHEMT), held at the Albany College of Pharmacy and Health Sciences, Albany, NY 12208, USA.
Dr. Diwan presented a talk entitled "Beyond Antibodies: Chemical Nanomachines to Combat Emerging Virus Threats" about the Nanoviricides technology and accomplishments in the first session at PHEMT.
Additionally, Dr. Diwan was invited to and presented a talk on "Nanomedicine Drug Development Regulatory Processes: Critical Issues" in the second session at PHEMT. He discussed that fundamentally nanomedicines were no different in terms of regulatory requirements, namely, safety, efficacy, and product quality. He further illuminated that, in contrast to small chemicals, the complex nature of nanomedicines requires significantly extensive work to develop manufacturing processes and characterization methods to meet the criterion of being able to produce a nanomedicine that will be equivalent from batch to batch. He also discussed how the scientists, mainly chemists and engineers, need to harness knowledge from various disciplines in order to build quality into nanomedicines manufacture.
The PHEMT conference was co-chaired by Raj Bawa, MS, PhD, Bawa Biotech LLC, Ashburn, VA and Adjunct Professor, Rensselaer Polytechnic Institute, Troy, NY; and Shaker A. Mousa, PhD, MBA, Vice Provost and Professor, Albany College of Pharmacy and Health Sciences, Albany, NY and Chairman & Executive Vice President, The Pharmaceutical Research Institute, Rensselaer, NY.
(www.nanoviricides.com) is a development stage company that is creating special purpose nanomaterials for
antiviral therapy. The Company's novel nanoviricide® class of drug candidates are designed to specifically attack enveloped virus particles and to
dismantle them. The Company is developing drugs against a number of viral diseases including H1N1 swine flu, H5N1 bird flu, seasonal Influenza, HIV,
oral and genital Herpes, viral diseases of the eye including EKC and herpes keratitis, Hepatitis C, Rabies, Dengue fever, and Ebola virus, among
This press release contains forward-looking statements that reflect the Company's current expectation regarding future events. Actual events could
differ materially and substantially from those projected herein and depend on a number of factors. Certain statements in this release, and other
written or oral statements made by NanoViricides, Inc. are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933
and Section 21E of the Securities Exchange Act of 1934. You should not place undue reliance on forward-looking statements since they involve known and
unknown risks, uncertainties and other factors which are, in some cases, beyond the Company's control and which could, and likely will, materially
affect actual results, levels of activity, performance or achievements. The Company assumes no obligation to publicly update or revise these
forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these
forward-looking statements, even if new information becomes available in the future. Important factors that could cause actual results to differ
materially from the company's expectations include, but are not limited to, those factors that are disclosed under the heading "Risk Factors" and
elsewhere in documents filed by the company from time to time with the United States Securities and Exchange Commission and other regulatory
authorities. Although it is not possible to predict or identify all such factors, they may include the following: demonstration and proof of
principle in preclinical trials that a nanoviricide is safe and effective; successful development of our product candidates; our ability to seek and
obtain regulatory approvals, including with respect to the indications we are seeking; the successful commercialization of our product candidates; and
market acceptance of our products.
FDA refers to US Food and Drug Administration. EMA refers to the European Union’s office of European Medical Agency.
Anil R. Diwan